2nd Immune Effector Cell Therapies in Multiple Myeloma Workshop
Building upon the success of the inaugural workshop held in April 2019, the International Myeloma Society is happy to host the 2nd Immune Effector Cell Therapies in Multiple Myeloma Workshop to discuss various immune-based therapies in myeloma including CART cell clinical data and promising preclinical leads, review the latest correlative analyses exploring predictors of response and resistance mechanisms, evaluate uniform practices in managing patients with CRS and other complications, and discuss next-generation cell therapy strategies, including “off-the-shelf” allogeneic and NK-cell based approaches. This year we are also including a session on cell-engaging bispecific antibody-based approaches.
2nd Immune Effector Cell Therapies in Multiple Myeloma Workshop Program
2nd Immune Effector Cell Therapies Health and Safety Plan
Thank you to our sponsors
Building upon the success of the inaugural workshop held in April 2019, the International Myeloma Society is happy to host the 2nd Immune Effector Cell Therapy in Multiple Myeloma Workshop to discuss various immune-based therapies in myeloma including CART cell clinical data and promising preclinical leads, review the latest correlative analyses exploring predictors of response and resistance mechanisms, evaluate uniform practices in managing patients with CRS and other complications, and discuss next-generation cell therapy strategies, including “off-the-shelf” allogeneic and NK-cell based approaches. This year we are also including a session on cell-engaging bispecific antibody-based approaches.
